Unknown candidate ligand: (i) Broad patient applicability via MR1 (limited-polymorphism); (ii) MR1 is upregulated in metabolically stressed/cancerous cells; (iii) MR1 ligand stability (e.g., 5-OP-RU) is limited; (iv) tumor-specific MR1 presentation not fully characterized (80). The gene discussed is MR1; the disease is neoplasm.